Figure 2.
Effects of acute and repeat administration of GSK189254 on mean duration (±SEM) of sleep–wake stages in a 4 h recording within the lights-on period in (A) wild-type (Ox+/+) and (B) Ox−/− mice (n= 14 per group). GSK189254 (3 and 10 mg·kg−1) significantly increased wakefulness (W) and decreased slow wave sleep (SWS) and paradoxical sleep (PS) following acute dosing. Repeat administration of GSK189254 (10 mg·kg−1, twice daily for 8 days) resulted in a reduction in effects on W, SWS and PS compared with acute dosing with 10 mg·kg−1. *P < 0.05, t-test between groups (compared with vehicle-treated mice) after significant anova. #P < 0.05, t-test between groups (compared with acute 10 mg·kg−1 dose group) after significant anova.